Dow Jones

40,211.72

0.53%

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

XLRN

Acceleron Pharma (XLRN)

Acceleron Pharma Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:XLRN

<< Anterior 1 2 3 4 5 6 7 8 9 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
01/04/2021	06:00	Business Wire	New England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arter...	NASDAQ:XLRN	Acceleron Pharma Inc
04/03/2021	16:18	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:XLRN	Acceleron Pharma Inc
25/02/2021	15:13	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:XLRN	Acceleron Pharma Inc
25/02/2021	15:04	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:XLRN	Acceleron Pharma Inc
25/02/2021	15:01	Business Wire	Acceleron Reports Fourth Quarter and Full Year 2020 Financial Results	NASDAQ:XLRN	Acceleron Pharma Inc
23/02/2021	06:00	Business Wire	Acceleron to Participate in Two Upcoming Healthcare Investor Conferences	NASDAQ:XLRN	Acceleron Pharma Inc
17/02/2021	06:00	Business Wire	Acceleron to Webcast Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021	NASDAQ:XLRN	Acceleron Pharma Inc
16/02/2021	11:34	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:XLRN	Acceleron Pharma Inc
16/02/2021	06:37	Business Wire	Health Canada Approves REBLOZYL® (luspatercept), New Class of Treatment for Adult Patients Living With Myelodysplastic Syndr...	NASDAQ:XLRN	Acceleron Pharma Inc
04/02/2021	06:10	Business Wire	Acceleron Announces Fourth Quarter and Full Year 2020 REBLOZYL® Net Sales	NASDAQ:XLRN	Acceleron Pharma Inc
04/01/2021	06:00	Business Wire	Acceleron to Participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021	NASDAQ:XLRN	Acceleron Pharma Inc
14/12/2020	06:00	Business Wire	Acceleron Receives Orphan Designation from the European Commission (EC) for Sotatercept in Pulmonary Arterial Hypertension (P...	NASDAQ:XLRN	Acceleron Pharma Inc
01/12/2020	06:00	Business Wire	Acceleron Receives FDA Orphan Drug Designation for ACE-1334 for the Treatment of Systemic Sclerosis	NASDAQ:XLRN	Acceleron Pharma Inc
13/11/2020	09:01	Business Wire	Acceleron Presents Preliminary Interim Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension ...	NASDAQ:XLRN	Acceleron Pharma Inc
13/11/2020	09:00	Business Wire	Acceleron Presents New Data from the PULSAR Phase 2 Trial, Preclinical Research on Sotatercept in Pulmonary Arterial Hyperten...	NASDAQ:XLRN	Acceleron Pharma Inc
09/11/2020	06:00	Business Wire	Acceleron Announces Clinical Trial Updates, Preclinical Presentation on Sotatercept in Pulmonary Arterial Hypertension at the...	NASDAQ:XLRN	Acceleron Pharma Inc
05/11/2020	15:15	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:XLRN	Acceleron Pharma Inc
05/11/2020	15:01	Business Wire	Acceleron Reports Third Quarter 2020 Operating and Financial Results	NASDAQ:XLRN	Acceleron Pharma Inc
05/11/2020	06:15	Business Wire	Acceleron Announces Third Quarter 2020 REBLOZYL® Net Sales	NASDAQ:XLRN	Acceleron Pharma Inc
04/11/2020	15:01	Business Wire	Acceleron Announces REBLOZYL® (luspatercept-aamt) Virtual Presentations at the 62nd American Society of Hematology Annual Me...	NASDAQ:XLRN	Acceleron Pharma Inc
26/10/2020	06:00	Business Wire	Acceleron to Webcast Third Quarter 2020 Operating and Financial Results on November 5, 2020	NASDAQ:XLRN	Acceleron Pharma Inc
29/09/2020	05:59	Business Wire	Health Canada Approves REBLOZYL® (luspatercept), New Class of Treatment for Adult Patients Living with Beta Thalassemia	NASDAQ:XLRN	Acceleron Pharma Inc
17/09/2020	15:01	Business Wire	Acceleron to Host Webcast Outlining the Design of Its Registrational Phase 3 STELLAR Trial of Sotatercept in Pulmonary Arteri...	NASDAQ:XLRN	Acceleron Pharma Inc
17/09/2020	08:13	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:XLRN	Acceleron Pharma Inc
16/09/2020	06:00	Business Wire	Acceleron Appoints Laura J. Hamill to its Board of Directors	NASDAQ:XLRN	Acceleron Pharma Inc
06/08/2020	15:01	Business Wire	Acceleron Reports Second Quarter 2020 Operating and Financial Results	NASDAQ:XLRN	Acceleron Pharma Inc
06/08/2020	06:10	Business Wire	Acceleron Announces Second Quarter 2020 REBLOZYL® Net Sales	NASDAQ:XLRN	Acceleron Pharma Inc
27/07/2020	06:00	Business Wire	Acceleron to Webcast Second Quarter 2020 Operating and Financial Results on August 6, 2020	NASDAQ:XLRN	Acceleron Pharma Inc
16/07/2020	16:01	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:XLRN	Acceleron Pharma Inc
07/07/2020	15:04	Business Wire	Acceleron Announces Closing of Public Offering of Common Stock & Exercise of Underwriters’ Option to Purchase Additional Sh...	NASDAQ:XLRN	Acceleron Pharma Inc